Outcomes in patients undergoing multivessel percutaneous coronary intervention using sirolimus-eluting stents: a report from the e-SELECT registry.
Cuculi, Florim; Banning, Adrian P.; Abizaid, Alexanderet al.
2011 • In EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 7 (8), p. 962-8
[en] AIMS: Performing percutaneous coronary intervention (PCI) to multiple coronary lesions during the same procedure has potential economic and social advantages. However comprehensive outcome data of real world practice in a large population is limited. We aimed to compare short- and long-term outcomes between patients with multivessel coronary artery disease who either underwent single- or multivessel PCI within the e-SELECT registry. METHODS AND RESULTS: The e-SELECT registry combines data collected at 320 medical centres in 56 countries where patients received CYPHER Select(R) or CYPHER Select(R) Plus sirolimus-eluting stent (SES). Rates of myocardial infarction and major adverse cardiac event (MACE) (defined as any death, myocardial infarction or target lesion revascularisation) were compared between patients undergoing single-vessel versus multivessel PCI. A total of 15,147 patients who satisfied the inclusion criteria were included in the e-SELECT registry. Two thousand two hundred and seventy-eight (2,278) subjects (15%) underwent multivessel PCI and 12,869 (85%) had single-vessel PCI. The mean age was higher in the multivessel PCI group (63 vs. 62 years, p<0.001) and there was a higher prevalence of diabetes mellitus (32.4 vs. 30.0%, p=0.02). Lesions were more complex in the single-PCI group while pre- and post-dilatation were less common in the multivessel PCI group. Myocardial infarction within the first 30 days post PCI was more common in the multivessel PCI group (1.9 vs. 0.8%, p<0.001) and most of the infarctions were periprocedural (1.3 vs. 0.6%, p=0.001). Mortality and myocardial infarction at one-year were higher in the multivessel PCI group resulting in a significantly higher MACE (6.1 vs. 4.6%, p=0.005). CONCLUSIONS: Overall procedural and one year outcomes were excellent for both single- and multivessel procedures. However despite lower lesion complexity, performing multivessel PCI was associated with higher rates of periprocedural myocardial infarction and MACE when compared to single-vessel PCI in the e-SELECT registry.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Cuculi, Florim
Banning, Adrian P.
Abizaid, Alexander
Bartorelli, Antonio L.
Baux, Ana C.
Dzavik, Vladimir
Ellis, Stepehen
Gao, Runlin
Holmes, David
Jeong, Myung H.
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305:1769-1776.
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-1907.
Feldman DN, Minutello RM, Gade CL, Wong SC. Outcomes following immediate (ad hoc) versus staged percutaneous coronary interventions (report from the 2000 to 2001 New York State Angioplasty Registry). Am J Cardiol. 2007;99:446-449.
Krone RJ, Shaw RE, Klein LW, Blankenship JC, Weintraub WS. Ad hoc percutaneous coronary interventions in patients with stable coronary artery disease - a study of prevalence, safety, and variation in use from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). Catheter Cardiovasc Interv. 2006;68:696-703. (Pubitemid 44721089)
Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2011;58:704-711.
Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Dzavik V, Ellis S, Gao R, Holmes D, Jeong MH, Legrand V, Neumann FJ, Nyakern M, Spaulding C, Worthley S. Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry. J Am Coll Cardiol. 2011;57:1445-1454.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
Moses JW, Weisz G, Mishkel G, Caputo R, O'Shaughnessey C, Wong SC, Fischell TA, Mooney M, Williams DO, Popma JJ, Fitzgerald P, Smith S, Kuntz RE, Collins M, Cohen SA, Leon MB. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv. 2007;70:505-512. (Pubitemid 47597020)
Hirohata A, Morino Y, Ako J, Sakurai R, Buchbinder M, Caputo RP, Karas SP, Mishkel GJ, Mooney MR, O'Shaughnessy C D, Raizner AE, Wilensky RL, Williams DO, Wong SC, Yock PG, Honda Y, Moses JW, Fitzgerald PJ. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial). Am J Cardiol. 2006;98:1464-1467. (Pubitemid 44779474)
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, 3rd, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL, Jr. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988;78:486-502.
Roy P, Steinberg DH, Sushinsky SJ, Okabe T, Pinto Slottow TL, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Weissman NJ, Lindsay J, Waksman R. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J. 2008;29:1851-1857.
Moses JW, Dangas G, Mehran R, Mintz GS. Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome. Am J Cardiol. 2008;102:24J-28J.
Basalus MW, Tandjung K, van Apeldoorn AA, Ankone MJ, von Birgelen C. Effect of oversized partial postdilatation on coatings of contemporary durable polymer-based drug-eluting stents: a scanning electron microscopy study. J Interv Cardiol. 2011;24:149-161.
Gao Z, Yang YJ, Xu B, Chen JL, Qiao SB, Yao M, Chen J, Wu YJ, Liu HB, Dai J, Yuan JQ, Li JJ, Gao RL. Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients. Chin Med J (Engl). 2008;121: 513-517. (Pubitemid 351479630)
Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM. 2009;102:369-378.
Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? Heart. 2010;96:736-740.
Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-847.
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.
